{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:36:13Z","timestamp":1789468573559,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016620","name":"Nick Simons Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016620","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30AI168436"],"award-info":[{"award-number":["P30AI168436"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Glob. Public Health"],"DOI":"10.1186\/s44263-026-00324-4","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:02:24Z","timestamp":1789462944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The epidemiological impact, costs, and cost-effectiveness of implementing household contact investigation with tuberculosis preventive treatment in Nepal: a model-based analysis"],"prefix":"10.1186","volume":"4","author":[{"given":"Rajan","family":"Paudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchal","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvesh","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunchok","family":"Dorjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Dhital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Caws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourya","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"324_CR1","unstructured":"Global Tuberculosis Report. 2024. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024. Accessed 17 Dec 2024."},{"key":"324_CR2","doi-asserted-by":"publisher","unstructured":"Velen K, Shingde RV, Ho J, Fox GJ. The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis. Eur Respir J. 2021;58. https:\/\/doi.org\/10.1183\/13993003.00266-2021.","DOI":"10.1183\/13993003.00266-2021"},{"key":"324_CR3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(22)01433-7","volume":"400","author":"GB Marks","year":"2022","unstructured":"Marks GB, Horsburgh CR, Fox GJ, Nguyen TA. Epidemiological approach to ending tuberculosis in high-burden countries. Lancet. 2022;400:1750\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(22)01433-7.","journal-title":"Lancet"},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. N Engl J Med. 2011;365:2155\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1104875.","journal-title":"N Engl J Med"},{"key":"324_CR5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.5588\/IJTLD.18.0168","volume":"22","author":"Y Hamada","year":"2018","unstructured":"Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc Lung Dis. 2018;22:1422\u20138. https:\/\/doi.org\/10.5588\/IJTLD.18.0168.","journal-title":"Int J Tuberc Lung Dis"},{"key":"324_CR6","doi-asserted-by":"publisher","unstructured":"Jo Y, Gomes I, Flack J, Salazar-Austin N, Churchyard G, Chaisson RE, et al. Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries. E Clinical Medicine. 2021;31. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100707.","DOI":"10.1016\/j.eclinm.2020.100707"},{"key":"324_CR7","doi-asserted-by":"publisher","first-page":"e1003712","DOI":"10.1371\/JOURNAL.PMED.1003712","volume":"18","author":"A Uppal","year":"2021","unstructured":"Uppal A, Rahman S, Campbell JR, Oxlade O, Menzies D. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Med. 2021;18:e1003712. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1003712.","journal-title":"PLoS Med"},{"key":"324_CR8","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1016\/S2214-109X(23)00251-6","volume":"11","author":"T Ryckman","year":"2023","unstructured":"Ryckman T, Weiser J, Gombe M, Turner K, Soni P, Tarlton D, et al. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health. 2023;11:e1205\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(23)00251-6.","journal-title":"Lancet Glob Health"},{"key":"324_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/J.CHEST.2015.11.017","volume":"149","author":"JM Trauer","year":"2016","unstructured":"Trauer JM, Moyo N, Tay EL, Dale K, Ragonnet R, McBryde ES, et al. Risk of Active Tuberculosis in the Five Years Following Infection. 15%? Chest. 2016;149:516\u201325. https:\/\/doi.org\/10.1016\/J.CHEST.2015.11.017.","journal-title":"15%? Chest"},{"key":"324_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(23)01231-X","volume":"402","author":"A Bhargava","year":"2023","unstructured":"Bhargava A, Bhargava M, Meher A, Benedetti A, Velayutham B, Sai Teja G, et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet. 2023;402:627\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(23)01231-X.","journal-title":"Lancet"},{"key":"324_CR11","unstructured":"National Tuberculosis Control Centre. National tuberculosis prevalence survey report. Ministry of Health and Population; Department of Health Services; National Tuberculosis control Center; 2020."},{"key":"324_CR12","unstructured":"National Tuberculosis Center. National Strategic Plan for Tuberculosis Prevention. Care and Control. Kathmandu; 2016."},{"key":"324_CR13","unstructured":"Ministry of Health and Population NTC. National Tuberculosis Management Guidelines. 2019."},{"key":"324_CR14","unstructured":"WHO. Evidence and research gaps identified during development of policy guidelines for tuberculosis. World Health Organ. 2021;1\u201326."},{"key":"324_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.5588\/IJTLD.21.0293","volume":"25","author":"O Oxlade","year":"2021","unstructured":"Oxlade O, den Boon S, Menzies D, Falzon D, Lane MY, Kanchar A, et al. TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up. Int J Tuberc Lung Dis. 2021;25:823. https:\/\/doi.org\/10.5588\/IJTLD.21.0293.","journal-title":"Int J Tuberc Lung Dis"},{"key":"324_CR16","first-page":"13","volume":"38","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Latent TB, Infection: Updated and consolidated guidelines for programmatic management. Patient Care. 2019;38:13\u20134. http:\/\/www.who.int\/tb\/publications\/2018\/latent-tuberculosis-infection\/en\/. Accessed 16 Dec 2024.","journal-title":"Patient Care"},{"key":"324_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.JVAL.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022;25:3\u20139. https:\/\/doi.org\/10.1016\/J.JVAL.2021.11.1351.","journal-title":"Value Health"},{"key":"324_CR18","doi-asserted-by":"publisher","unstructured":"Paudel R. The epidemiological impact, costs, and cost-effectiveness of implementing household contact investigation with tuberculosis preventive treatment in Nepal: a model-based analysis | Zenodo. https:\/\/doi.org\/10.5281\/zenodo.21790325. Accessed 4 Aug 2026.","DOI":"10.5281\/zenodo.21790325"},{"key":"324_CR19","unstructured":"DoHS_Annual_Report 207879. (202122) TB Part \u2013 National TB Control Center. https:\/\/nepalntp.gov.np\/publications\/dohs_annual_report-207879-202122-tb-part\/. Accessed 28 Mar 2025."},{"key":"324_CR20","unstructured":"National Population and and Housing Census. 2021 Results. https:\/\/censusnepal.cbs.gov.np\/results. Accessed 28 Mar 2025."},{"key":"324_CR21","unstructured":"National Tuberculosis Control Center. Clinical Handbook of Tuberculosis Management 2024 | National Tuberculosis Control Center Bhaktapur. 2024."},{"key":"324_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-021-02110-5","volume":"19","author":"S Shrestha","year":"2021","unstructured":"Shrestha S, Kendall EA, Chang R, Joseph R, Kasaie P, Gillini L, et al. Achieving a step change in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis. BMC Med. 2021;19:1\u201315. https:\/\/doi.org\/10.1186\/S12916-021-02110-5.","journal-title":"BMC Med"},{"key":"324_CR23","doi-asserted-by":"publisher","unstructured":"Shrestha S, Mishra G, Hamal M, Dhital R, Shrestha S, Shrestha A, et al. Quantifying the potential epidemiological impact of a 2-year active case finding for tuberculosis in rural Nepal: a model-based analysis. BMJ Open. 2023;13. https:\/\/doi.org\/10.1136\/BMJOPEN-2022-062123.","DOI":"10.1136\/BMJOPEN-2022-062123"},{"key":"324_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/TROPICALMED8070369","volume":"8","author":"SC Gurung","year":"2023","unstructured":"Gurung SC, Dixit K, Paudel R, Sah MK, Pandit RN, Aryal TP, et al. Comparing Additionality of Tuberculosis Cases Using GeneXpert or Smear-Based Active TB Case-Finding Strategies among Social Contacts of Index Cases in Nepal. Trop Med Infect Dis. 2023;8:369. https:\/\/doi.org\/10.3390\/TROPICALMED8070369.","journal-title":"Trop Med Infect Dis"},{"key":"324_CR25","unstructured":"A Global Database of Inflation. https:\/\/www.worldbank.org\/en\/research\/brief\/inflation-database. Accessed 22 Dec 2024."},{"key":"324_CR26","unstructured":"Global Drug Facility (GDF). | Stop TB Partnership. https:\/\/www.stoptb.org\/what-we-do\/facilitate-access-tb-drugs-diagnostics\/global-drug-facility-gdf. Accessed 4 Jun 2026."},{"key":"324_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016;19:929\u201335. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017.","journal-title":"Value Health"},{"key":"324_CR28","unstructured":"GDP per capita (current US$.) - Nepal | Data. https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?end=2022&locations=NP&start=1960. Accessed 15 Jun 2026."},{"key":"324_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S0140-6736(03)15332-9","volume":"363","author":"S Verver","year":"2004","unstructured":"Verver S, Warren RM, Munch Z, Richardson M, Van Der Spuy GD, Borgdorff MW, et al. Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet. 2004;363:212\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(03)15332-9.","journal-title":"Lancet"},{"key":"324_CR30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/AJE\/KWX025","volume":"185","author":"L Martinez","year":"2017","unstructured":"Martinez L, Shen Y, Mupere E, Kizza A, Hill PC, Whalen CC. Transmission of Mycobacterium Tuberculosis in Households and the Community: A Systematic Review and Meta-Analysis. Am J Epidemiol. 2017;185:1327. https:\/\/doi.org\/10.1093\/AJE\/KWX025.","journal-title":"Am J Epidemiol"},{"key":"324_CR31","unstructured":"NATIONAL STRATEGIC PLAN TO END TUBERCULOSIS IN. NEPAL 2021\/22-2025\/26 \u2013 National TB Control Center. https:\/\/nepalntp.gov.np\/publications\/national-strategic-plan-to-end-tuberculosis-in-nepal-2021-22-2025-26-english-ver\/. Accessed 28 Mar 2025."},{"key":"324_CR32","unstructured":"CRITIC Project- The Comprehensive Strategy for Retention in TB Infection Cascade of Care \u2013 Birat Nepal Medical Trust. https:\/\/bnmtnepal.org.np\/projects\/critic-project-the-comprehensive-strategy-for-retention-in-tb-infection-cascade-of-care\/. Accessed 8 Aug 2025."},{"key":"324_CR33","doi-asserted-by":"publisher","unstructured":"Pellis L, Cauchemez S, Ferguson NM, Fraser C. Systematic selection between age and household structure for models aimed at emerging epidemic predictions. Nature Communications 2020 11:1. 2020;11:1\u201311. https:\/\/doi.org\/10.1038\/s41467-019-14229-4","DOI":"10.1038\/s41467-019-14229-4"},{"key":"324_CR34","doi-asserted-by":"publisher","first-page":"e8479","DOI":"10.1371\/JOURNAL.PONE.0008479","volume":"5","author":"E Brooks-Pollock","year":"2010","unstructured":"Brooks-Pollock E, Cohen T, Murray M. The Impact of Realistic Age Structure in Simple Models of Tuberculosis Transmission. PLoS ONE. 2010;5:e8479. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0008479.","journal-title":"PLoS ONE"},{"key":"324_CR35","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/S12879-020-05592-5","volume":"20","author":"T Sumner","year":"2020","unstructured":"Sumner T, White RG. The predicted impact of tuberculosis preventive therapy: the importance of disease progression assumptions. BMC Infect Dis. 2020;20:880. https:\/\/doi.org\/10.1186\/S12879-020-05592-5.","journal-title":"BMC Infect Dis"},{"key":"324_CR36","doi-asserted-by":"publisher","first-page":"e1004356","DOI":"10.1371\/JOURNAL.PMED.1004356","volume":"21","author":"FC Semitala","year":"2024","unstructured":"Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, et al. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024;21:e1004356. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1004356.","journal-title":"PLoS Med"},{"key":"324_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/TMI.13940","volume":"28","author":"N Sharma","year":"2023","unstructured":"Sharma N, Bakshi R, Basu S, Zode M, Arora R, Khanna A. Implementation of tuberculosis preventive therapy with INH-Rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: A prospective study. Trop Med Int Health. 2023;28:890\u2013900. https:\/\/doi.org\/10.1111\/TMI.13940.","journal-title":"Trop Med Int Health"},{"key":"324_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/TROPICALMED9010004","volume":"9","author":"MT Rahman","year":"2023","unstructured":"Rahman MT, Hossain F, Banu RS, Islam MS, Alam S, Faisel AJ, et al. Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid\u2013Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study. Trop Med Infect Dis. 2023;9:4. https:\/\/doi.org\/10.3390\/TROPICALMED9010004.","journal-title":"Trop Med Infect Dis"},{"key":"324_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Millet J, Cayl\u00e0 J, Wright A, Chen M, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017;167:689. https:\/\/doi.org\/10.7326\/M17-1150.","journal-title":"Ann Intern Med"},{"key":"324_CR40","doi-asserted-by":"publisher","first-page":"e1679","DOI":"10.1016\/S2214-109X(21)00367-3","volume":"9","author":"NA Menzies","year":"2021","unstructured":"Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021;9:e1679. https:\/\/doi.org\/10.1016\/S2214-109X(21)00367-3.","journal-title":"Lancet Glob Health"}],"container-title":["BMC Global and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44263-026-00324-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44263-026-00324-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44263-026-00324-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:02:34Z","timestamp":1789462954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s44263-026-00324-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1186\/s44263-026-00324-4","relation":{},"ISSN":["2731-913X"],"issn-type":[{"value":"2731-913X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and ethical approval was obtained for this study from Nepal Health Research Council (Protocol registration number: 326\/2021). Written informed consent was obtained from all participants included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}